Literature DB >> 19118698

Association of vitreous inflammatory factors with diabetic macular edema.

Hideharu Funatsu1, Hidetaka Noma, Tatsuya Mimura, Shuichiro Eguchi, Sadao Hori.   

Abstract

PURPOSE: To evaluate the association between vitreous inflammatory factors and the severity of diabetic macular edema (DME).
DESIGN: Retrospective case-control study. PARTICIPANTS: Fifty-three patients with DME, 15 patients with nondiabetic ocular disease, and 8 diabetic patients without retinopathy.
METHODS: Vitreous fluid samples were obtained during vitreoretinal surgery, and the levels of vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM)-1, interleukin (IL)-6, monocyte chemotactic protein (MCP)-1, and pigment epithelium-derived factor (PEDF) were measured by enzyme-linked immunosorbent assay. Multivariate analysis was performed to assess the association of these factors with the severity of DME. MAIN OUTCOME MEASURES: Vitreous fluid levels of inflammatory factors.
RESULTS: Vitreous fluid levels of VEGF, ICAM-1, IL-6, and MCP-1 were significantly higher in patients with DME than in nondiabetic patients (P<0.05, all respectively) or diabetic patients without retinopathy (P<0.05, all respectively). In contrast, the PEDF level was significantly lower in patients with DME than in nondiabetic patients (P<0.05) or diabetic patients without retinopathy (P<0.05). Vitreous levels of VEGF, ICAM-1, IL-6, and MCP-1 were significantly higher in patients with hyperfluorescent DME than in those with minimally fluorescent DME (P = 0.0018, P = 0.0022, P = 0.0032, and P = 0.0053, respectively). Conversely, the vitreous level of PEDF was significantly lower in hyperfluorescent DME than in minimally fluorescent DME (P = 0.0134). Vitreous levels of VEGF, ICAM-1, IL-6, MCP-1, and PEDF were significantly correlated with the retinal thickness at the central fovea (P<0.0001, P<0.0001, P = 0.0282, P = 0.0009, and P = 0.0466, respectively). VEGF and ICAM-1 had a stronger influence on the severity of DME than the other factors (P = 0.0004 and P = 0.0372, respectively).
CONCLUSIONS: Vitreous fluid levels of VEGF, ICAM-1, IL-6, MCP-1, and PEDF were related to retinal vascular permeability and the severity of DME. VEGF and ICAM-1 had a stronger influence than the other factors. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any materials discussed in this article.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118698     DOI: 10.1016/j.ophtha.2008.09.037

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  147 in total

Review 1.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

2.  Efficacy of Ozurdex implant in recalcitrant diabetic macular edema--a single-center experience.

Authors:  Pooja Bansal; Vishali Gupta; Amod Gupta; Mangat Ram Dogra; Jagat Ram
Journal:  Int Ophthalmol       Date:  2015-08-02       Impact factor: 2.031

3.  Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.

Authors:  Lisa J Faia; H Nida Sen; Zhuqing Li; Steven Yeh; Keith J Wroblewski; Robert B Nussenblatt
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-01       Impact factor: 4.799

4.  A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Authors:  David G Callanan; Anat Loewenstein; Sunil S Patel; Pascale Massin; Borja Corcóstegui; Xiao-Yan Li; Jenny Jiao; Yehia Hashad; Scott M Whitcup
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-08       Impact factor: 3.117

Review 5.  Therapeutic Options in Refractory Diabetic Macular Oedema.

Authors:  Sanket U Shah; Raj K Maturi
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

6.  Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.

Authors:  Katja Hatz; Andreas Ebneter; Cengiz Tuerksever; Christian Pruente; Martin Zinkernagel
Journal:  Ophthalmologica       Date:  2018-02-02       Impact factor: 3.250

7.  Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Authors:  Farzin Forooghian; Peter J Kertes; Kenneth T Eng; Elvira Agrón; Emily Y Chew
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

8.  [Cytokine determination from vitreous samples in retinal vascular diseases].

Authors:  M Pfister; F H Koch; J Cinatl; F Rothweiler; R Schubert; P Singh; H Ackermann; M J Koss
Journal:  Ophthalmologe       Date:  2013-08       Impact factor: 1.059

9.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01

10.  Role of IL-6 in angiotensin II-induced retinal vascular inflammation.

Authors:  Modesto Rojas; Wenbo Zhang; Dexter L Lee; Maritza J Romero; Doan T Nguyen; Mohamed Al-Shabrawey; Nai-Tse Tsai; Gregory I Liou; Michael W Brands; Robert W Caldwell; Ruth B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-15       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.